Effect of thyroid hormone on the activity of CYP3A enzyme in humans

Journal of Clinical Pharmacology

Volumn 50, Issue 1, 2010, Pages 88-93

  Takahashi, Norio ^a   Inui, Naoki ^a   Morita, Hiroshi ^a   Takeuchi, Kazuhiko ^a   Uchida, Shinya ^b   Watanabe, Hiroshi ^a   Nakamura, Hirotoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

6 hydroxycortisol; Cytochrome P450 3A; Cytochrome P450 3A4; Human; Midazolam; Pharmacokinetics; Thyroid hormone

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; HYDROCORTISONE DERIVATIVE; LIOTHYRONINE; MIDAZOLAM; MIDAZOLAM MALEATE; THYROID HORMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; MALE; OPEN STUDY; URINE LEVEL; VOLUNTEER;

ADULT; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; HYDROCORTISONE; MALE; MIDAZOLAM; MIDDLE AGED; THYROID HORMONES; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 72749105866     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009344336     Document Type: Article

References (26)

1. Boucher BA, Wood GC, Swanson JM Pharmacokinetic changes in critical illness. Crit Care Clin. 2006 ; 22: 255-271.
2. Sarlis NJ, Gourgiotis L. Hormonal effects on drug metabolism through the CYP system: perspectives on their potential significance in the era of pharmacogenomics. Curr Drug Targets Immune Endocr Metabol Disord. 2005 ; 5: 439-448.
3. Weetman AP Graves? disease. N Engl J Med. 2000 ; 343: 1236-1248.
4. Harvey CB, Williams GR Mechanism of thyroid hormone action. Thyroid. 2002 ; 12: 441-446.
5. Rowland M., Tozer TN Clinical Pharmacokinetics: Concepts and Applications. 3 rd ed. Baltimore, MD: Williams & Wilkins ;1995: 119-183.
6. Thomas FB, Caldwell JH, Greenberger NJ Steatorrhea in thyrotoxicosis: relation to hypermotility and excessive dietary fat. Ann Intern Med. 1973 ; 78: 669-675.
7. Bonelli J., Haydl H., Hruby K., Kaik G. The pharmacokinetics of digoxin in patients with manifest hyperthyroidism and after normalization of thyroid function. Int J Clin Pharmacol. 1978 ; 16: 302-306.
8. Feely J. Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease. Clin Pharmacokinet. 1983 ; 8: 1-16.
9. Crooks J., Hedley AJ, MacNee C., Stevenson IH Changes in drug metabolizing ability in thyroid disease. Br J Pharmacol. 1973 ; 49: 156.
10. Vesell ES, Shapiro JR, Passananti T., Jorgensen H., Shively CA Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction. Clin Pharmacol Ther. 1975 ; 17: 48-56.
11. Hallengren B., Nilsson OR, Karlberg BE, Melander A., Tegler L., W?hlin-Boll E. Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1982 ; 21: 379-384.
12. Tsubokawa T., Yamamoto K., Kobayashi T. Propofol clearance and distribution volume increase in patients with hyperthyroidism. Anesth Analg. 1998 ; 87: 195-199.
13. Vargas F., Moreno JM, Rodrguez-G?3mez I., et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006 ; 154: 197-212.
14. Zhang QY, Dunbar D., Ostrowska A., Zeisloft S., Yang J., Kaminsky LS Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos. 1999 ; 27: 804-809. (Pubitemid 29297778)
15. Guengerich FP Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999 ; 39: 1-17.
16. Liddle C., Goodwin BJ, George J., Tapner M., Farrell GC Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab. 1998 ; 83: 2411-2416.
17. Andersson U., Yang YZ, Bj?rkhem I., Einarsson C., Eggertsen G., G?fvels M. Thyroid hormone suppresses hepatic sterol 12alphahydroxylase (CYP8B1) activity and messenger ribonucleic acid in rat liver: failure to define known thyroid hormone response elements in the gene. Biochim Biophys Acta. 1999 ; 1438: 167-174.
18. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe, II: characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther. 1994 ; 271: 557-566.
19. Chung E., Nafziger AN, Kazierad DJ, Bertino JS Jr. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther. 2006 ; 79: 350-361.
20. Joellenbeck L., Qian Z., Zarba A., Groopman JD Urinary 6 betahydroxycortisol/cortisol ratios measured by high-performance liquid chromatography for use as a biomarker for the human cytochrome P-450 3A4. Cancer Epidemiol Biomarkers Prev. 1992 ; 1: 567-572.
21. Ruder H., Corvol P., Mahoudeau JA, Ross GT, Lipsett MB Effects of induced hyperthyroidism on steroid metabolism in man. J Clin Endocrinol Metab. 1971 ; 33: 382-387.
22. Yan D., Yang Y., Uchida S., et al. Effects of ursodeoxycholic acid on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam in healthy volunteers. Naunyn Schmiedebergs Arch Pharmacol. 2008 ; 377: 629-636.
23. Holtzman CW, Wiggins BS, Spinler SA Role of P-glycoprotein in statin drug interactions. Pharmacotherapy. 2006 ; 26: 1601-1607.
24. Simsek G., Uzun H., Karter Y., Aydin S., Yigit G. Effects of osteoporotic cytokines in ovary-intact and ovariectomised rats with induced hyperthyroidism: is skeletal responsiveness to thyroid hormone altered in estrogen deficiency ? Tohoku J Exp Med. 2003 ; 201: 81-89.
25. Senturk T., Kozaci LD, Kok F., Kadikoylu G., Bolaman Z. Proinflammatory cytokine levels in hyperthyroidism. Clin Invest Med. 2003 ; 26: 58-63.
26. Takasu N., Akamine H., Komiya I., Yamada T. Simple and reliable method for predicting the remission of Graves? disease: revised triiodothyronine- suppression test, indexed by serum thyroxine. J Endocrinol Invest. 1995 ; 18: 288-294.